Financial analysts and market researchers tracking PainChek Limited (trading on the Australian Securities Exchange under the ticker PCK) maintain a consensus average 12-month target price hovering near 0.08 Australian dollars. Projections reflect the micro-cap nature of the digital health enterprise, balancing the international commercial rollout and institutional adoption of its smartphone-based pain assessment software against early-stage financial scaling timelines.